Clinical trials in multiple sclerosis - The importance of the outcome measure

被引：0
|
作者：
Zajicek, J
Thompson, A
Hobart, J
机构：
[1] Peninsula Med Sch, Plymouth, Devon, England
[2] Derriford Hosp, Plymouth PL6 8DH, Devon, England
[3] UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2004年 / 75卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
013
引用
收藏
页码：1215 / 1215
页数：1
相关论文
共 50 条
  • [21] Cutting the cost and length of clinical trials - the importance of choosing the right outcome measure
    Zajicek, J
    Thompson, A
    Hobart, J
    [J]. JOURNAL OF NEUROLOGY, 2004, 251 : 152 - 153
  • [22] Imaging as an Outcome Measure in Multiple Sclerosis
    Daniel Ontaneda
    Robert J. Fox
    [J]. Neurotherapeutics, 2017, 14 : 24 - 34
  • [23] Imaging as an Outcome Measure in Multiple Sclerosis
    Ontaneda, Daniel
    Fox, Robert J.
    [J]. NEUROTHERAPEUTICS, 2017, 14 (01) : 24 - 34
  • [24] Development of a multiple sclerosis functional composite as a clinical trial outcome measure
    Cutter, GR
    Baier, ML
    Rudick, RA
    Cookfair, DL
    Fischer, JS
    Petkau, J
    Syndulko, K
    Weinshenker, BG
    Antel, JP
    Confavreux, C
    Ellison, GW
    Lublin, F
    Miller, AE
    Rao, SM
    Reingold, S
    Thompson, A
    Willoughby, E
    [J]. BRAIN, 1999, 122 : 871 - 882
  • [25] Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
    Bernard M. J. Uitdehaag
    [J]. CNS Drugs, 2018, 32 : 543 - 558
  • [26] OUTCOME MEASURES FOR CLINICAL-TRIALS IN MULTIPLE-SCLEROSIS - REPLY
    MCFARLAND, HF
    [J]. ANNALS OF NEUROLOGY, 1992, 31 (01) : 116 - 117
  • [27] Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
    Uitdehaag, Bernard M. J.
    [J]. CNS DRUGS, 2018, 32 (06) : 543 - 558
  • [28] Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis
    Koch, Marcus W.
    Mostert, Jop
    Repovic, Pavle
    Bowen, James D.
    Uitdehaag, Bernard
    Cutter, Gary
    [J]. NEUROLOGY, 2021, 96 (01) : E111 - E120
  • [29] Appropriate design and outcome measures in multiple sclerosis clinical trials - Response
    Khan, OA
    Tselis, AC
    Kamholz, JA
    Garbern, JY
    Lewis, RA
    Lisak, RP
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 (05) : 505 - 506
  • [30] Measuring fatigue in multiple sclerosis clinical trials: why patient reported outcome measure choice is not immaterial when measuring change
    Hobart, Jeremy
    King, Tanya
    Sappl, Sonia
    Marais, Ida
    Close, James
    Vo, Pamela
    Andrich, David
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 450 - 451
12345